The Clinical Utility of HER2-Targeted Therapy in the Neoadjuvant Setting: Recent Results From the San Antonio Breast Cancer Symposium
- 1 February 2011
- journal article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 11 (1), 15-19
- https://doi.org/10.3816/cbc.2011.n.003
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro StudyJournal of Clinical Oncology, 2010
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab TherapyJournal of Clinical Oncology, 2010
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortThe Lancet, 2010
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor ModelsCancer Research, 2009
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancerNature Clinical Practice Oncology, 2008
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Research and Treatment, 2008